Prosecution Insights
Last updated: August 06, 2026
Application No. 18/295,520

CONTACT LENS COMPOSITIONS AND METHODS OF USE THEREOF

Final Rejection §102
Filed
Apr 04, 2023
Priority
Oct 12, 2016 — provisional 62/407,271 +8 more
Examiner
PALLAY, MICHAEL B
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ps Therapy Inc.
OA Round
2 (Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
406 granted / 729 resolved
-4.3% vs TC avg
Strong +35% interview lift
Without
With
+34.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
50 currently pending
Career history
776
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
47.6%
+7.6% vs TC avg
§102
12.0%
-28.0% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 729 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status Applicant’s response dated 28 May 2026 to the previous Office action dated 02 December 2025 is acknowledged. Pursuant to amendments therein, claims 1-22 are pending in the application. The claim objections made in the previous Office action are withdrawn in view of applicant’s claim amendments. The rejection under 35 U.S.C. 102 made in the previous Office action is withdrawn in view of applicant’s claim amendments, but a new (modified) rejection under 35 U.S.C. 102 is made herein in view of applicant’s claim amendments. Election/Restrictions Claims 1-13 and 16-22 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 19 August 2025. Claims 14-15 are under current consideration. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 14-15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Horn ‘006 (US 8,933,006 B1; issued 13 January 2015; of record). Regarding claims 14-15, Horn ‘006 discloses a contact lens cleaning composition comprising 5.00% w/v polyoxyl 40 stearate (i.e., a polyoxyethyleneglycol alkyl ether, PEG-40 stearate), 0.20% w/v poloxamer 407, 0.10% w/v poloxamer 188, and NaCl (Table 1 Composition 15), reading on the claimed contact lens storage composition comprising two or more nonionic surfactants selected from polyoxyethyleneglycol alkyl ethers and poloxamers at a total concentration from about 3.0% to about 5.9% w/v and sodium chloride, given that the claimed term “storage” merely implies an intended use of the composition that imposes no structure or steps not otherwise recited in the claim, and given that the total concentration of polyoxyl 40 stearate, poloxamer 407, and poloxamer 188 nonionic surfactants is 5.3% w/v (i.e., 5% + 0.20% + 0.10% w/v). Further regarding claims 14-15, Horn ‘006 discloses that the composition of Table 1 is instilled as drops to contact lens wearers complaining of dry, uncomfortable lenses after 16 hours of continuous contact lens use which provided long-lasting relief upon instillation with improved comfort (column 5 lines 5-14) wherein the method of the invention is directed to a method of cleaning a contact lens while the contact lens remains on the eye (column 1 lines 5-14), reading on the claimed method of enhancing contact lens comfort comprising administering the composition to a subject in need thereof of claim 14 and the claimed method of enhancing contact lens wear time comprising administering the composition to a subject in need thereof of claim 15. Response to Arguments Applicant's arguments filed 28 May 2026 have been fully considered but they are not persuasive. Applicant argues that the claims exclude polyoxyl 40 stearate (remarks page 7). In response, the claims do not exclude polyoxyl 40 stearate in that the claims include polyoxyethyleneglycol alkyl ethers, and polyoxyl 40 stearate (i.e., PEG-40 stearate) is a polyoxyethyleneglycol alkyl ether. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL B. PALLAY whose telephone number is (571)270-3473. The examiner can normally be reached Monday through Friday from 8:30 AM to 5:00 PM Eastern Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at (571)272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL B. PALLAY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Apr 04, 2023
Application Filed
Dec 02, 2025
Non-Final Rejection mailed — §102
May 28, 2026
Response Filed
Jun 17, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12691078
STABLE COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME
3y 10m to grant Granted Jul 28, 2026
Patent 12690592
SYSTEMS AND METHODS FOR USE OF CHLORINE DIOXIDE IN CULTIVATION AND POST-HARVEST APPLICATIONS
3y 0m to grant Granted Jul 28, 2026
Patent 12673028
THERAPEUTIC POTENTIAL OF CELLULOSE-CYCLODEXTRIN-CURCUMIN NANOCRYSTALS IN THE TREATMENT OF PERIPHERAL NEUROPATHIES
4y 5m to grant Granted Jul 07, 2026
Patent 12642773
COATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME
1y 12m to grant Granted Jun 02, 2026
Patent 12611396
Microsphere-Based Injectible Celecoxib Formulation
4y 3m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
90%
With Interview (+34.7%)
3y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 729 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month